This article describes a 3D microfluidic paper-based analytical device that can be used to conduct an enzymelinked immunosorbent assay (ELISA). The device comprises two parts: a sliding strip (which contains the active sensing area) and a structure surrounding the sliding strip (which holds stored reagents—buffers, antibodies, and enzymatic substrate—and distributes fluid). Running an ELISA involves adding sample (e.g. blood) and water, moving the sliding strip at scheduled times, and analyzing the resulting color in the sensing area visually or using a flatbed scanner. We demonstrate that this device can be used to detect C-reactive protein (CRP)—a biomarker for neonatal sepsis, pelvic inflammatory disease, and inflammatory bowel diseases—at a concentration range of 1–100 ng/mL in 1000-fold diluted blood (1–100 µg/mL in undiluted blood). The accuracy of the device (as characterized by the area under the receiver operator characteristics curve) is 89% and 83% for cutoffs of 10 ng/mL (for neonatal sepsis and pelvic inflammatory disease) and 30 ng/mL (for inflammatory bowel diseases) CRP in 1000-fold diluted blood respectively. In resource-limited settings, the device can be used as a part of a kit (containing the device, a fixed-volume capillary, a pre-filled tube, a syringe, and a dropper); this kit would cost ~ $0.50 when produced in large scale (> 100,000 devices/week). This kit has the technical characteristics to be employed as a pre-screening tool, when combined with other data such as patient history and clinical signs.
Cheap, rapid screening for diseases such as Ebola and tuberculosis could save lives in remote and impoverished places
Saving Lives at Birth: A Grand Challenge for Development combines six partner organizations in an effort to find new innovations and approaches to protect the health of infants and mothers worldwide.
The article, entitled "Flexible opto-electronics enabled microfluidics systems with cloud connectivity for point-of-care micronutrient analysis"...
This month, Diagnostics For All (DFA) celebrated a new achievement with their Liver Function Test (LFT): receiving certifications for ISO 13485:2013 in both Canadian and UK markets.
In a new article entitled ""Point-of-Care Diagnostics in Low Resource Settings: Present Status and Future Role of Microfluidics"...
FIND Chairman Mark Kessel lists DFA one of several key partners for developing affordable diagnostics in Nature BioTechnology magazine.
Interested in reading more? Search the full archive.